Grand Pharmaceutical & Glenmark Specialty Secure China NMPA Approval for Ryaltris Nasal Spray
Grand Pharmaceutical Group Limited (HKG: 0512) together with Glenmark Specialty S.A. announced that the Ryaltris...
Grand Pharmaceutical
Grand Pharma Launches GPN00884 Clinical Trial to Tackle Pediatric Myopia Progression
Grand Pharmaceutical Group Limited (HKG: 0512), a China-based company, announced on October 26, 2025, that...
Grand Pharma Secures CE Mark for SIR‑Spheres Y‑90, Expanding Liver‑Cancer Treatment Portfolio
Grand Pharmaceutical Group Limited (HKG: 0512) announced that SIR‑Spheres Y‑90 resin microsphere injection (brand name:...
Grand Pharma Partners with IRE EliT to Distribute 68Ge/68Ga Generators in China
On July 31, 2025, China-based Grand Pharmaceutical Group Limited (HKG: 0512) announced a strategic collaboration...
Grand Pharma’s TLX591 Granted NMPA Approval for Phase III Prostate Cancer Trial
China-based Grand Pharmaceutical Group Limited (HKG: 0512) announced that its innovative radiolabeled drug conjugate (RDC)...
Grand Pharma’s SIR-Spheres Y-90 Gets FDA Accelerated Approval for Unresectable HCC
China-based Grand Pharmaceutical Group Limited (HKG: 0512) announced that SIR-Spheres Y-90 resin microspheres (SIR-Spheres), a...
Bio-heart Launches Iberis Renal Ablation System at OCC 2025
China-based Shanghai Bio-heart Biological Technology Co., Ltd (HKG: 2185) hosted the product launch of its...
Grand Pharma’s GPN01768 Approved in Macau for Demodectic Blepharitis
Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) announced that its New Drug Application (NDA) for...
Grand Pharma’s Chengdu RDC Megafactory Secures Class A Radiation Safety License
Grand Pharmaceutical Group Limited (HKG: 0512) has obtained a Class A Radiation Safety License from...
Grand Pharma Completes Patient Enrollment for TLX591-CDx Phase III Trial
Grand Pharmaceutical Group Limited (HKG: 0512) announced the completion of patient enrollment for the Phase...
Grand Pharma Receives NMPA Review for Phase III Trial of TLX591 in Prostate Cancer
China-based Grand Pharmaceutical Group Limited (HKG: 0512) announced that a filing to conduct a Phase...
Grand Pharma’s AcornMed utLIFE-UC Urothelial Carcinoma Assay First Prescription Administered in China
China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) announced the first prescription of AcornMed utLIFE-UC,...
Grand Pharma Group and Sirtex Medical US Launch Commercial Partnership in Medical Innovation
China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) announced that its subsidiary Chengdu Shetai Medical...
Grand Pharma Secures NMPA Approval for Fluticasone Nasal Spray
China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) has obtained marketing authorization from China’s National...
Grand Pharma’s GPN02006 Shows Promising HCC Diagnostic Results in Trial
China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) has reported excellent outcomes from the investigator-initiated...
Grand Pharmaceutical Group Reports Strong 2024 Financials with 12.8% Revenue Growth
China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) revealed its 2024 financial performance, recording revenues...
Grand Pharma Sells Telix Shares for AUD 143M to Fund Clinical Programs
China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) announced the sale of 4,947,181 shares in...
Grand Pharmaceutical to Boost Stake in Nanjing Kainite Medical Technology via Exercise of Partial Subscription Rights
Grand Pharmaceutical Group Limited (HKG: 0512) announced on February 21, 2025, that it plans to...
Telix Pharmaceuticals’ TLX591-CDx Approved in Europe via Decentralized Procedure
Australia-based Telix Pharmaceuticals Ltd (ASX: TLX) has announced that the marketing filing in Europe via...
Grand Pharmaceutical Initiates Study on GPN00289 for Liver Cancer Treatment
China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) has announced the first patient enrollment in...